Stock Research for DCTH

DCTH

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

DCTH Stock Chart & Research Data

The DCTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DCTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


DCTH Due diligence Resources & Stock Charts

The DCTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DCTH Detailed Price Forecast - CNN Money CNN View DCTH Detailed Summary - Google Finance
Yahoo View DCTH Detailed Summary - Yahoo! Finance Zacks View DCTH Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View DCTH Trends & Analysis - Trade-Ideas Barrons View DCTH Major Holders - Barrons
NASDAQ View DCTH Call Transcripts - NASDAQ Seeking View DCTH Breaking News & Analysis - Seeking Alpha
Spotlight View DCTH Annual Report - CompanySpotlight.com OTC Report View DCTH OTC Short Report - OTCShortReport.com
TradeKing View DCTH Fundamentals - TradeKing Charts View DCTH SEC Filings - Bar Chart
WSJ View Historical Prices for DCTH - The WSJ Morningstar View Performance/Total Return for DCTH - Morningstar
MarketWatch View the Analyst Estimates for DCTH - MarketWatch CNBC View the Earnings History for DCTH - CNBC
StockMarketWatch View the DCTH Earnings - StockMarketWatch MacroAxis View DCTH Buy or Sell Recommendations - MacroAxis
Bullish View the DCTH Bullish Patterns - American Bulls Short Pains View DCTH Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View DCTH Stock Mentions - StockTwits PennyStocks View DCTH Stock Mentions - PennyStockTweets
Twitter View DCTH Stock Mentions - Twitter Invest Hub View DCTH Investment Forum News - Investor Hub
Yahoo View DCTH Stock Mentions - Yahoo! Message Board Seeking Alpha View DCTH Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for DCTH - SECform4.com Insider Cow View Insider Transactions for DCTH - Insider Cow
CNBC View DCTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DCTH - OTC Markets
Yahoo View Insider Transactions for DCTH - Yahoo! Finance NASDAQ View Institutional Holdings for DCTH - NASDAQ


Stock Charts

FinViz View DCTH Stock Insight & Charts - FinViz.com StockCharts View DCTH Investment Charts - StockCharts.com
BarChart View DCTH Stock Overview & Charts - BarChart Trading View View DCTH User Generated Charts - Trading View




Latest Financial News for DCTH


Delcath Announces Third Quarter Fiscal 2018 Financial Results
Posted on Tuesday November 13, 2018

NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces.


Delcath Announces Enrollment of First Patient in ALIGN Trial
Posted on Thursday October 18, 2018

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that patient treatments have begun in the Company’s second global US registration trial investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in the treatment of patients with intrahepatic cholangiocarcinoma (ICC). The University of Tennessee Health Science Center (UTHSC) in collaboration with Methodist University Hospital (MUH) and West Cancer Center (WCC) in Memphis, Tennessee have enrolled the trial’s first patient and treatments have begun by a team led by Dr. Evan S. Glazer.


Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
Posted on Monday October 15, 2018

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amended trial protocol for the company’s registration trial in ocular melanoma liver metastases.


Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
Posted on Thursday October 04, 2018

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been published in the journal European Radiology. The study is the first analysis on the use of Delcath’s PHP® Therapy for the treatment of ICC. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France with Dr. Steffen Marquardt of Hannover Medical School serving as lead author.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.